NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Neurocrine Biosciences Inc is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - Specialty & Generic industry.
Neurocrine Biosciences is a biopharmaceutical company that develops and sells treatments for disorders affecting the brain, mood, hormones, and immune system. The company markets three FDA-approved medications addressing tardive dyskinesia, Huntington's disease chorea, and congenital adrenal hyperplasia, plus endometriosis and uterine fibroids with AbbVie. Its pipeline contains experimental drugs across multiple therapeutic areas using varied approaches.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Neurocrine Biosciences Inc stock.
Undervalued: intrinsic value $200.93 per share, market price $136.98, margin of safety 31.8% (as of 2026-10-19).
Discounting its cash flows at 7.7% (average of 3 methods) values the shares at $200.93; the price of $136.98 is 32% below that value, and 82% of that value comes from beyond year five.
Leak Score: 90/100 on 11 of 12 signals (Major Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
4 more in this industry show a wider margin of safety.
NBIX is undervalued (as of the 2026-10-19 close). Discounting its cash flows at 7.7% (average of 3 methods) values the shares at $200.93; the price of $136.98 is 32% below that value, and 82% of that value comes from beyond year five.
$200.93 per share (as of the 2026-10-19 close), against a market price of $136.98. That is a margin of safety of 31.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
90 out of 100, which we rate "Major Leak", on 11 of 12 value investing signals.